News - Pharmaceutical, Xolair

Filter

Current filters:

PharmaceuticalXolair

Popular Filters

Novartis presents strong new Ph III results with omalizumab in CSU

Novartis presents strong new Ph III results with omalizumab in CSU

05-10-2013

Novartis has presented new results from the Phase III ASTERIA I study showing omalizumab was effective…

DermatologicalsGenentechNovartisOmalizumabPharmaceuticalResearchXolair

UK's NICE approves NHS funding for Novartis' Xolair for all eligible patients

24-07-2013

The UK's drugs watch dog the National Institute for Health and Care Excellence (NICE) has stipulated…

EuropeHealthcareNovartisPharmaceuticalRespiratory and PulmonaryXolair

UK's NICE gives final guidance on Esbriet, Orencia and Xolair

24-04-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has today (April 24) published…

Anti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbEsbrietEuropeInterMuneNovartisOrenciaPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

NICE makes U-turn, recommending Novartis' Xolair for children aged six-11 years

07-03-2013

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) has today (March 7)…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

UK's NICE revokes NHS use of Novartis' Xolair for asthma in children and adults

09-11-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryXolair

Back to top